GlaxoSmithKline has signed a licensing agreement worth up to €445.5 million euros ($577 million) for global rights to an experimental rheumatoid arthritis drug developed by German antibody specialist MorphoSys.
News
GSK-spin off Autifony kicks off PhI hearing loss trial
GlaxoSmithKline spin-off group Autifony Therapeutics has kicked off a Phase I trial of its experimental drug designed to tackle hearing disorders, with financial backing from Pfizer’s venture capital arm, among others.
NICE moves to improve bowel disorder diagnoses
The National Institute for Health and Care Excellence has published draft guidance which it hopes will help improve the diagnosis of serious bowel conditions.
Risk-based monitoring needed to boost clinical trial success
Greater use of risk-based monitoring (RBM) in clinical trials is needed to modernise the drug development process, says industry consortium TransCelerate BioPharma.
UK business hamstrung by lack of support for innovation
A parliamentary report claiming the UK’s science base is being held back by a lack of support from government for technological innovation will be debated next week.
Wellcome-backed clinical research unit opens in Ireland
A €7 million clinical research facility has opened at St James’ Hospital in Dublin, Ireland, to carry out early- and late-phase clinical trials across a range of therapeutic categories.
Fujifilm and Dr Reddy’s break off Japanese joint venture
Japanese group Fujifilm and India’s Dr Reddy’s have decided to break off plans to form an exclusive partnership to develop generic drugs for the Japanese market and establish a joint venture in the country.
NHS managers prepare for post-Francis world
The head of the NHS Confederation is warning that sticking plasters on ‘creaking parts of the NHS’ will soon fail, and only NHS leaders must “take up the gauntlet” and respond to the increasing pressures and challenges that lay ahead.
Sanofi terminates Phase III lung cancer and heart drugs
Sanofi has suffered a clinical setback and is pulling the plug on two late-stage drugs, iniparib for lung cancer and the anticoagulant otamixaban.
Sun Pharma rumoured to be looking at Meda bid
Shares in Sun Pharmaceutical Industries have fallen back on rumours it is in talks to buy Sweden’s Meda in the region of $5 billion.
UK licenses first therapy for adults diagnosed with ADHD
Eli Lilly’s Strattera has become the first medicine in the UK to be approved specifically for treatment initiation in adults with attention-deficit hyperactivity disorder (ADHD).
Amgen quietly confident over melanoma immunotherapy
Among the plethora of data being presented on melanoma treatments at the American Society of Clinical Oncology meeting in Chicago, Amgen has presented promising detailed late-stage data on talimogene laherparepvec, also known as T-Vec.
Call for breast cancer trials for younger women
A new study has found that clinical trials for breast cancer are not including enough younger women, which could be affecting treatment outcomes.
Celgene myeloma drug heads latest CHMP opinions
The latest set of opinions from advisors to the European Medicines Agency sees seven new medicines recommended for approval.
Vinegar cervical cancer test will save thousands
A major trial in India has taken centre-stage at the American Society of Clinical Oncology meeting in Chicago after it demonstrated that a simple test using vinegar has slashed the rates of cervical cancer mortality in the country.
